Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
News|Articles|May 30, 2025
OncLive’s FDA Approval Report: The Regulatory Rundown for May 2025
Author(s)OncLive Staff
Fact checked by: Kristi Rosa
Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.
Advertisement
Advertisement
Below is your guide to all the oncologic therapeutic options cleared by the FDA in May 2025. The roundup provides everything you need to know, right at your fingertips—all the topline data that supported the decisions and expert insights contextualizing what they mean for clinical practice.
Related to this article
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
Patients with resected RCC given adjuvant durvalumab with or without tremelimumab described persistent low-grade toxicities as most disruptive to QOL.
Advertisement
Advertisement